Humira is a prescription medication used to relieve the symptoms of certain autoimmune disorders. It is used to treat certain kinds of arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, ulcerative colitis and hidradenitis suppurativa (a chronic inflammatory skin disease).
Humira is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation.
This medication comes in an injectable form in prefilled syringes. Humira is injected just under the skin usually once every other week.
Common side effects of Humira include reactions at the injection site, sinus infections, and headaches.
SERIOUS INFECTIONS
- Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.
- Humira should be discontinued if a patient develops a serious infection or sepsis during treatment.
- Perform test for latent TB; if positive, start treatment for TB prior to starting Humira.
- Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
MALIGNANCY
- Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which Humira is a member.
- Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including Humira.
